Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 59

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 59
---
 dimensional
data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine
Learning (“AI/ML”) has emerged as a digital solution to help address this problem.

We
use artificial intelligence and machine learning to advance medicines for both internal and external projects. We are committed to increasing
the probability of success and decreasing the time and cost involved in developing therapeutics. Most current AI/ML platforms still fall
short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™,
is an analytical AI/ML platform derived from technology developed at The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”),
which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a
more precise1, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical
stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining
data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics,
and impacting the lives of countless patients that may otherwise not receive the therapies they need.

1
In an August 2021 publication in DeepAI.org (https://deepai.org/publication/random-subspace-mixture-models-for-interpretable-anomaly-detection),
the algorithms used in bfLEAP were compared to 10 of the most popular clustering algorithms in the world using 12 data sets. The end
result showed that the algorithms used in bfLEAP had the highest average score when measuring speed and accuracy of prediction. The bfLEAP
platform currently has more advanced versions of these algorithms and is applying them in multiple data analytics projects.

 4 

Recent Developments

In
February 2025, we announced our entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase
III oncology company focused on novel chemotherapeutic treatments for rare cancers. Through this collaboration, we will apply our proprietary
Bullfrog Data Networks™ solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison’s ongoing Phase
III trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. The platform will evaluate
the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety performance
from prior studies to support future trial design, and provide